Biotech’s New Frontiers: CAR-T, CRISPR, Psychedelics
Kilder
- Nature: CAR-neutrophils produced in vivo to treat glioma - Nature
- nature.com: CAR-neutrophils produced in vivo to treat glioma - Nature
- Bioworld: Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest - BioWorld News
- bioworld.com: Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest - BioWorld News
- bioworld.com: CHMP gives nod for Sanofi’s Cenrifki for multiple sclerosis - BioWorld News
- Statnews: FDA to speed up review of three psychedelics as mental health treatments - statnews.com
- statnews.com: FDA to speed up review of three psychedelics as mental health treatments - statnews.com
- nbcnews.com: FDA grants quick review for 3 psychedelic drug trials - NBC News
- wral.com: FDA plans ultra-fast review of three psychedelic drugs following Trump directive - WRAL
- Biospace: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer - BioSpace
- biospace.com: Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer - BioSpace
- Labiotech: Modified CRISPR tool targets Down syndrome mutation - Labiotech.eu
- labiotech.eu: Modified CRISPR tool targets Down syndrome mutation - Labiotech.eu
- Fiercebiotech: After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy? - Fierce Biotech
- fiercebiotech.com: After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy? - Fierce Biotech
- drugdiscoverynews.com: Weekly Rundown: Lilly expands in vivo CAR T push with $7B Kelonia deal - Drug Discovery News
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.